Hsa_circ_0000190 Promotes NSCLC Cell Resistance to Cisplatin via the Modulation of the miR‐1253/IL‐6 Axis
Analytical Cellular Pathology · 2024
DOI: 10.1155/2024/6647810 ↗Kurz gefasst
Fachartikel in der Zeitschrift Analytical Cellular Pathology, 2024. Verfasst von Hua He und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory, Nanjing Chest Hospital, Affiliated Nanjing Brain Hospital, Nanjing Medical University, No. 215, Guangzhou Road, Nanjing 21…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, MicroRNAs. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
This study explored the mechanistic basis for nonsmall cell lung cancer (NSCLC) cisplatin (DDP) treatment resistance in an effort to define effective approaches to abrogating the emergence of such chemoresistance.
Methods
Analyses of NSCLC expression of hsa_circ_0000190, miR‐1253, and interleukin 6 (IL‐6) were conducted via a quantitative real‐time polymerase chain reaction (qPCR) approach, while the ability of these tumor cells to resist DDP treatment was evaluated with a CCK‐8 assay. Interactions between different RNA molecules were assessed using both RNA immunoprecipitation and dual‐luciferase reporter assays.
Results
NSCLC cell lines and tissues resistant to DDP were found to express higher levels of hsa_circ_0000190, and knocking down this circRNA in NSCLC cells was associated with greater sensitivity to DDP exposure. Further research identified miR‐1253 as a hsa_circ_0000190 target, with the ability of hsa_circ_0000190 knockdown to restore DDP sensitivity being largely attributable to the ability of this circRNA to suppress miR‐1253 activity. IL‐6 was identified as a major miR‐1253 target in this context, with miR‐1253 regulating chemoresistance in NSCLC cells in part by preventing IL‐6 upregulation.
Conclusion
Together, these data suggest that hsa_circ_0000190 can promote DDP chemoresistance in NSCLC cells through its ability to modulate miR‐1253/IL‐6 axis activity, highlighting a novel pathway that can be targeted in an effort to guide the more effective diagnosis and management of DDP‐resistant tumors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Respiratory, Nanjing Chest Hospital, Affiliated Nanjing Brain Hospital, Nanjing Medical University, No. 215, Guangzhou Road, Nanjing 210029, China.
ORCID-Profile: Tian Li
Zitieren
APA
He, H., & Li, T. (2024). Hsa_circ_0000190 Promotes NSCLC Cell Resistance to Cisplatin via the Modulation of the miR‐1253/IL‐6 Axis. Analytical Cellular Pathology. https://doi.org/10.1155/2024/6647810
Vancouver
He H, Li T. Hsa_circ_0000190 Promotes NSCLC Cell Resistance to Cisplatin via the Modulation of the miR‐1253/IL‐6 Axis. Analytical Cellular Pathology. 2024. doi:10.1155/2024/6647810
BibTeX
@article{He2024,
author = {He, Hua and Li, Tian},
title = {Hsa_circ_0000190 Promotes NSCLC Cell Resistance to Cisplatin via the Modulation of the miR‐1253/IL‐6 Axis},
journal = {Analytical Cellular Pathology},
year = {2024},
doi = {10.1155/2024/6647810}
}
EUVIMED